Document is current

Article History

Received: 22 March 2024

Accepted: 28 April 2024

First Online: 6 May 2024

Declarations

:

: The authors declare no competing interests. WM declares no conflict of interest relevant to this study. NK has participated in meetings sponsored by, received speaker honoraria or travel funding from Alexion, BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). CM declares no conflict of interest relevant to this study. MM declares no conflict of interest relevant to this study. NM declares no conflict of interest relevant to this study. KN declares no conflict of interest relevant to this study. SZ declares no conflict of interest relevant to this study. CW has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grünenthal, Hermes, Novartis, Pfizer, Ratiopharm/Teva, and Stada. BP declares no conflict of interest relevant to this study. GB has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis. WM study concept and design, acquisition of data, rating of MRI images, interpretation of data, critical revision of manuscript for intellectual content. NK acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. CM acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. MM acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. NM acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. KN acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. SZ acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. CW acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. BP acquisition of data, interpretation of data, critical revision of manuscript for intellectual content. GB study concept and design, acquisition of data, statistical analysis and interpretation of data, drafting of manuscript, study supervision.